Figure 1.

The Omicron SARS-CoV-2 variant BA.1.1 exhibits strong vaccine-induced immune escape that is overcome by booster vaccination

(A) Diagrams of SARS-CoV-2 S variants used for pseudotyping, which indicate the location of specific mutations as well as the S1 and S2 subunits of S, the N-terminal domain (NTD), receptor binding domain (RBD), fusion peptide (FP), and transmembrane domain (TM).

(B) Sera from 48 HCWs collected 3–4 weeks after second mRNA vaccine dose were used to neutralize pseudotyped variants, and the resulting 50% neutralization titers (NT₅₀) are displayed.

(C) Heatmaps showing patient/vaccinee NT₅₀ values against each variant with patient numbers identified as “M” for Moderna mRNA-1273-vaccinated/boosted HCW and “P” for Pfizer/BioNTech BNT162b2-vaccinated/boosted HCW.

(D) Sera from 19 HCWs following homologous mRNA booster vaccination were assessed for nAb titers. Geometric mean NT₅₀ values in (B) and (D) are displayed at the top of plots along with the percent of subjects with NT₅₀ values above the limit of detection; bars represent geometric mean ±95% confidence interval, and significance relative to D614G is determined by one-way repeated measures ANOVA with Bonferroni’s multiple testing correction. P values are represented as ^∗p < 0.05, ^∗∗∗p < 0.001, ^∗∗∗∗p < 0.0001; ns, not significant.

See also Figure S1.